These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26555472)

  • 1. Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition.
    Tie C; Gao K; Zhang N; Zhang S; Shen J; Xie X; Wang JA
    PLoS One; 2015; 10(11):e0142430. PubMed ID: 26555472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
    Guo X; Wang L; Xia X; Wang P; Li X
    Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Antiatherogenic Properties of Ezetimibe Using
    Dumas LS; Briand F; Clerc R; Brousseau E; Montemagno C; Ahmadi M; Bacot S; Soubies A; Perret P; Riou LM; Devoogdt N; Lahoutte T; Barone-Rochette G; Fagret D; Ghezzi C; Sulpice T; Broisat A
    J Nucl Med; 2017 Jul; 58(7):1088-1093. PubMed ID: 28280218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ezetimibe on atherosclerosis in preclinical models.
    Davis HR; Lowe RS; Neff DR
    Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
    Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
    Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
    Oh PC; Jang AY; Ha K; Kim M; Moon J; Suh SY; Lee K; Han SH; Kang WC
    Am J Cardiol; 2021 Sep; 154():22-28. PubMed ID: 34238445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
    Salic K; Morrison MC; Verschuren L; Wielinga PY; Wu L; Kleemann R; Gjorstrup P; Kooistra T
    Atherosclerosis; 2016 Jul; 250():158-65. PubMed ID: 27236706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
    Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atorvastatin inhibits the atherosclerotic lesion induced by tumor necrosis factor-like weak inducer of apoptosis in apolipoprotein E deficient mice].
    Fernández-Laso V; Sastre C; Egido J; Martín-Ventura JL; Blanco-Colio LM
    Clin Investig Arterioscler; 2015; 27(1):17-25. PubMed ID: 25027757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect.
    Gómez-Garre D; Muñoz-Pacheco P; González-Rubio ML; Aragoncillo P; Granados R; Fernández-Cruz A
    Br J Pharmacol; 2009 Apr; 156(8):1218-27. PubMed ID: 19222481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
    Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
    Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation.
    Umemoto T; Subramanian S; Ding Y; Goodspeed L; Wang S; Han CY; Teresa AS; Kim J; O'Brien KD; Chait A
    J Lipid Res; 2012 Nov; 53(11):2380-9. PubMed ID: 22956784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol-independent effects of atorvastatin prevent cardiovascular morbidity and mortality in a mouse model of atherosclerotic plaque rupture.
    Roth L; Rombouts M; Schrijvers DM; Martinet W; De Meyer GR
    Vascul Pharmacol; 2016 May; 80():50-8. PubMed ID: 26826559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe.
    Sato K; Nakano K; Katsuki S; Matoba T; Osada K; Sawamura T; Sunagawa K; Egashira K
    J Atheroscler Thromb; 2012; 19(11):986-98. PubMed ID: 22785139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.